PBMCs from stage IV melanoma patients after vaccination with melanoma-targeted mature dendritic cells (mDCs).
Ontology highlight
ABSTRACT: Patients affected by stage IV melanoma were subjected to a first round of DC vaccination in two centres, then PBMCs were extracted and mRNA analysed using Illumina arrays for identifying signals related to a favourable outcome of the therapy in terms of survival. A panel of candidate markers was further verified by real time PCR on PBMCs from patients treated with the same vaccination protocol in additional centres. This multi-centric study allowed to identify the gene PEBP1 as a candidate biomarker for vaccination positive outcome. The data released here was used to derive the first panel of markers.
INSTRUMENT(S): Illumina HumanHT-12 V3.0, Ambion RNA mirvanaâ¢Â extraction kit, Agilent 2100 Bioanalyzer, Nanodrop ND-1000 spectrophotometer, Illumina TotalPrep-96 RNA Amplification Kit
ORGANISM(S): Homo sapiens
SUBMITTER: Matteo Ramazzotti
PROVIDER: E-MTAB-5201 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA